Featuring perspectives from Dr Dana M Chase, including the following topics:

• Introduction: ASCO 2024 Review (0:00)
• Ovarian Cancer (14:29)
• HER2 as a Therapeutic Target (29:18)
• Endometrial Cancer (38:55)
• Cervical Cancer (51:11)

CME information and select publications

Featuring an interview with Dr Jonathan W Goldman, including the following topics:

• Contemporary and Future Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation (0:00)
• Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation (21:05)
• Other Emerging Strategies for Relapsed Metastatic Lung Cancer (29:16)
• Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation (37:59)
• Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation (45:29)

CME information and select publications

Featuring perspectives from Dr Nikhil I Khushalani and Dr Jason J Luke, including the following topics:

• Introduction (0:00)
• Evidence-Based Treatment of Nonmetastatic and Metastatic Melanoma — Dr Luke (2:49)
• Optimizing the Management of Nonmelanoma Skin Cancers — Dr Khushalani (36:54)

CME information and select publications

Featuring perspectives from Dr Rana R McKay and Prof Thomas Powles, including the following topics:

• Introduction (0:00)
• Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Prof Powles (12:39)
• Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr McKay (49:27)

CME information and select publications

Featuring perspectives from Dr Scott Kopetz and Dr John Strickler, including the following topics:

• Introduction (0:00)
• Recent Therapeutic Advances in Colorectal Cancer (CRC) — Dr Strickler (1:53)
• New Developments in Targeted Therapy for Metastatic CRC — Dr Kopetz (35:11)

CME information and select publications

Featuring perspectives from Dr Joshua Brody, Dr Ian W Flinn and Dr Tycel Phillips, including the following topics:

• Introduction: CD3 Bispecific Antibodies in the Community Oncology Setting (0:00)
• Integration of Bispecific Antibody Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Phillips (18:13)
• Current and Future Role of Bispecific Antibodies in Follicular Lymphoma and Other B-Cell Lymphomas — Dr Flinn (41:20)
• Tolerability and Other Practical Considerations with the Use of Bispecific Antibody Therapy — Dr Brody(50:49)

CME information and select publications

Featuring perspectives from Dr Kevin Kalinsky and Dr Heather McArthur, including the following topics:

• Introduction (0:00)
• Case: A woman in her mid 80s with a 2.7-cm residual tumor after neoadjuvant pembrolizumab/chemotherapy for localized triple-negative breast cancer (TNBC) — Ranju Gupta, MD (3:31)
• Question and Comments: Approach to neoadjuvant therapy and defining residual disease; PD-L1 status and efficacy of pembrolizumab in the localized and metastatic settings — Kapisthalam (KS) Kumar, MD (8:04)
• Case: A woman in her mid 60s with node-positive TNBC and a single lung metastasis who receives neoadjuvant therapy based on the KEYNOTE-522 trial — Dr Kumar (17:18)
• Case: A woman in her early 70s with localized TNBC and residual disease after poorly tolerated neoadjuvant pembrolizumab/chemotherapy and lumpectomy — Dr Kumar (23:29)
• Case: A woman in her late 60s with widely metastatic ER-negative, HER2-low disease after multiple lines of treatment — CDH1 and ERBB2-V697L mutations, microsatellite stable, tumor mutational burden 3 mut/Mb — Dr Gupta (29:13)
• Question and Comments: Adjuvant therapy selection for patients with localized TNBC with a BRCA mutation and residual disease; risk of acute myeloid leukemia/myelodysplastic syndromes associated with PARP inhibitor therapy — Dr Kumar (40:52)
• Case: A woman in her early 70s who develops recurrent metastatic ER-negative, HER2-low breast cancer after nab paclitaxel/atezolizumab and receives sacituzumab govitecan — Dr Gupta (46:49)

CME information and select publications

Featuring perspectives from Dr Rafael Fonseca, Dr María-Victoria Mateos and Dr Elizabeth O’Donnell, moderated by Dr O’Donnell, including the following topics:

• Introduction (0:00)
• Treatment Approaches for Newly Diagnosed Multiple Myeloma (MM) — Dr Fonseca (2:05)
• Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with MM — Dr Mateos (22:06)
• Incorporation of Other Novel Agents and Strategies into the Management of Relapsed/Refractory MM — Dr O’Donnell (39:25)

CME information and select publications